Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors
Phase of Trial: Phase IV
Latest Information Update: 18 Jun 2019
Price : $35 *
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Therapeutic Use
- Acronyms VACIRiSS
- 25 Mar 2019 Recruitment completion is expected on 31 Jan 2020, according to ISRCTN: Current Controlled Trials record.
- 10 Dec 2018 The recruitment start date is 01/08/2018 and the recruitment end date of this study is 31/01/2020.
- 20 Sep 2018 Status changed from not yet recruiting to recruiting.